TARDBP
TARDBP encodes TDP-43, a nuclear RNA-binding protein that regulates splicing and RNA stability across many neuronal transcripts. In ALS and many forms of frontotemporal dementia, TDP-43 becomes depleted from the nucleus and accumulates in cytoplasmic aggregates.
Key Takeaways
- •TARDBP encodes TDP-43, a nuclear RNA-binding protein that regulates splicing and RNA stability.
- •TDP-43 pathology in ALS and many FTD cases includes nuclear depletion and cytoplasmic aggregates.
- •Loss of nuclear TDP-43 function can drive mis-splicing of key neuronal genes such as STMN2 and UNC13A.
- •Therapeutic strategies target RNA processing, stress granule biology, and downstream pathways rather than a single enzyme.
Basic Information
- Gene Symbol
- TARDBP
- Full Name
- TAR DNA Binding Protein
- Also Known As
- TDP-43ALS10
- Location
- 1p36.22
- Protein Type
- RNA-binding protein
- Protein Family
- hnRNP-like RBP family
Related Isoforms
Key SNPs
Pathogenic TARDBP mutation associated with familial ALS and altered TDP-43 aggregation propensity.
ALS-associated mutation in the C-terminal low-complexity region, linked to altered phase behavior.
Reported ALS-associated mutation in TARDBP with effects on TDP-43 biology and toxicity.
Example of a TARDBP missense variant linked to ALS in some cohorts.
Mutation reported in ALS/FTD contexts, affecting the aggregation-prone C-terminal domain.
Well-known TARDBP mutation associated with ALS and altered TDP-43 localization.
Reported familial ALS mutation affecting the C-terminal region implicated in stress granules and aggregation.
Overview
TARDBP encodes TDP-43, a nuclear RNA-binding protein that regulates splicing, RNA stability, and transport. TDP-43 binds thousands of transcripts and helps maintain neuronal RNA programs that support synaptic function and axonal integrity.
In ALS and many forms of frontotemporal dementia, TDP-43 becomes depleted from the nucleus and accumulates as cytoplasmic phosphorylated aggregates. This creates a combined toxicity profile: loss of nuclear RNA regulation plus gain-of-toxicity from aggregated or mislocalized species.
Conceptual Model
A simplified mental model for the pathway:
Both nuclear loss-of-function and cytoplasmic aggregation contribute to disease, which complicates biomarker interpretation and targeting.
Core Health Impacts
- • RNA processing: Regulates splicing and stability of neuronal transcripts.
- • Axonal health: Maintains axonal and synaptic proteins through RNA processing programs.
- • Phase behavior: Stress granule biology intersects with TDP-43 phase behavior and aggregation risk.
- • Splicing control: Nuclear depletion can drive cryptic exon inclusion and loss of key neuronal functions.
- • Proteinopathy: Cytoplasmic TDP-43 aggregates are a hallmark of ALS and many FTD cases.
Protein Domains
N-terminal domain
Supports protein interactions and contributes to overall TDP-43 stability and localization.
RNA recognition (RRM)
Bind RNA and regulate splicing and transcript stability. Loss can disrupt neuronal gene programs.
C-terminal region
Prion-like domain implicated in stress granules and aggregation. Most ALS mutations cluster here.
Upstream Regulators
Cellular stress Activator
Stress promotes TDP-43 relocalization into stress granules, increasing aggregation risk.
Transport balance Activator
Disruption of nuclear transport can promote cytoplasmic accumulation of TDP-43.
Modifications Activator
Phosphorylation and ubiquitination can shift TDP-43 solubility and aggregation propensity.
RNA binding load Activator
High RNA processing demand can increase vulnerability to TDP-43 dysfunction.
Clearance capacity Inhibitor
Autophagy and proteasome determine whether misfolded TDP-43 accumulates.
Neuroinflammation Activator
Inflammatory signaling can amplify stress pathways and alter RNA processing.
Downstream Targets
RNA splicing Activates
TDP-43 regulates splicing and stability. Nuclear loss causes widespread mis-splicing.
STMN2 Activates
TDP-43 loss triggers cryptic processing, reducing axonal regeneration capacity.
UNC13A Activates
TDP-43 dysfunction induces cryptic exon inclusion, linking RNA to synaptic failure.
Stress granules Activates
Altered phase behavior can shift RNA-protein assemblies toward persistent aggregates.
Synapses Activates
Downstream effects include synaptic failure, axonal degeneration, and glia loops.
Inclusions Activates
Cytoplasmic phosphorylated TDP-43 aggregates are a major pathology in ALS and FTD.
Role in Aging
Aging increases vulnerability to RNA processing stress and proteostasis failure. Declines in nuclear transport, chaperones, and lysosomal function can increase the probability of TDP-43 mislocalization, aggregation, and loss of nuclear splicing control.
Proteostasis decline
Reduced autophagy and proteasome capacity increases persistence of misfolded RBPs and stress granule remnants.
Energy stress
Energy deficits increase cellular stress signaling and can bias RNA-protein assemblies toward persistent aggregation states.
Lysosomal bottleneck
Impaired lysosomal degradation increases accumulation of aggregated proteins and reduces clearance of cytoplasmic inclusions.
Sleep and clearance
Poor sleep can increase inflammatory tone and reduce waste clearance, amplifying stress on vulnerable neurons.
Nuclear transport drift
Age-related changes in nuclear pore and transport factors can increase the chance of TDP-43 cytoplasmic accumulation.
Inflammaging
Chronic low-grade inflammation can amplify glial activation and accelerate neuron-glia stress loops in ALS and FTD.
Disorders & Diseases
Amyotrophic Lateral Sclerosis
TDP-43 pathology is present in the majority of ALS cases. TARDBP mutations are a rare cause of familial ALS.
Frontotemporal Dementia
Many FTD cases are TDP-43 proteinopathies, with executive and behavioral changes driven by network degeneration.
ALS-FTD Spectrum
ALS and FTD share molecular mechanisms and pathology. TARDBP sits at the center of this overlap through RNA biology.
RNA Splicing Disorders
TDP-43 loss-of-function can induce widespread mis-splicing and transcript instability, damaging neuronal maintenance programs.
Functional Decline
ALS progression is tracked with functional scales, respiratory measures, and biomarkers such as neurofilament light.
Interventions
Supplements
May support inflammation balance and membrane health, indirectly affecting neurodegeneration trajectories.
Redox support and glutathione precursor studied in neurodegeneration contexts.
Supports sleep quality and excitability balance, which can affect stress vulnerability.
Immune-modulating hormone with associations to inflammation control.
Energy-buffering compound studied for neuromuscular support.
Lifestyle
Tracking respiratory function supports timely planning and interventions in ALS.
Maintains function and reduces secondary complications from weakness.
Maintaining nutrition supports resilience; dysphagia often requires proactive planning.
Sleep quality influences stress and inflammation, which intersect with neurodegeneration vulnerability.
Medicines
Standard ALS therapy that modestly slows progression in some patients.
Antioxidant therapy used in ALS in some settings; evidence and patient selection vary.
Treat spasticity, cramps, saliva, mood, and sleep issues to support function and quality of life.
Experimental therapies that modulate RNA processing or assemblies are an active research area.
Lab Tests & Biomarkers
Genetic Testing
Clinical sequencing confirms pathogenic TARDBP variants in suspected familial cases.
Panels may include TARDBP, C9orf72, SOD1, FUS, and other associated genes.
Fluid Biomarkers
Non-specific marker of axonal injury used for prognosis tracking in ALS and FTD.
Direct TDP-43 biomarkers remain challenging; research assays are in development.
Clinical/Physiology
Functional rating scale commonly used to track ALS progression over time.
Respiratory function tests guide planning and timing of supportive interventions.
Hormonal Interactions
Cortisol Stress Factor
Chronic elevation can worsen sleep and metabolic control and can amplify inflammatory signaling.
Thyroid hormone Metabolic Regulator
Thyroid dysfunction can worsen fatigue and weakness.
Insulin Metabolic Link
Brain insulin resistance is associated with impaired proteostasis and stress pathways.
Testosterone Body Composition
Hormonal status influences muscle mass and recovery, affecting function.
Estrogen Neuroimmune
Sex hormones influence immune tone and may modulate neuroinflammatory pathways.
Melatonin Circadian
Supports sleep architecture, linked to stress resilience.
Deep Dive
Network Diagrams
TDP-43 Mislocalization and Aggregation
TDP-43 Loss-of-Function Consequences
Nuclear Loss and Cytoplasmic Aggregation
A defining feature of TDP-43 proteinopathy is nuclear depletion paired with cytoplasmic accumulation. This creates a dual-hit mechanism: loss of normal RNA processing and gain of toxicity from aggregates and stress granule persistence.
Mislocalization: Stress and transport defects can shift TDP-43 from nucleus to cytoplasm.
Phase transitions: The low-complexity C-terminal region can promote phase separation that becomes less reversible, increasing aggregation risk.
Proteostasis overload: Persistent assemblies burden proteasome and autophagy systems and can disrupt neuronal homeostasis.
Cryptic Splicing and Loss of Neuronal Programs
Loss of nuclear TDP-43 can induce cryptic splicing events that reduce expression of key neuronal genes. Two well-studied examples are STMN2, important for axonal regeneration, and UNC13A, important for synaptic function.
STMN2 loss: TDP-43 dysfunction can trigger cryptic processing that lowers functional STMN2, weakening axonal repair capacity.
UNC13A loss: Cryptic exon inclusion can reduce UNC13A function, linking RNA biology to synaptic failure and disease progression.
Stress Granules and Phase Behavior
TDP-43 participates in stress-responsive RNA-protein assemblies. Under chronic stress, assemblies can become less reversible, increasing the probability of persistent aggregates and sustained nuclear depletion.
This links cellular stress, nuclear transport, and proteostasis into a single axis that can drive progressive RNA dysregulation and neurodegeneration.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Identified TDP-43 as a major protein component of pathological inclusions in ALS and FTD.
Established that TARDBP mutations can cause ALS and linked sequence changes to disease biology.
Connected TDP-43 loss-of-function to STMN2 dysregulation, linking splicing to axonal repair failure.
Linked TDP-43 dysfunction to UNC13A splicing and to genetic modifiers of ALS and FTD.